TRPA1 recombinant proteins and antibodies

Transient receptor potential ankyrin 1 (TRPA1) is a non-selective cation channel that is permeable to Ca2+, thereby increasing intracellular Ca2+ levels. TRPA1 is of particular interest because it responds to a variety of environmental stimuli and is involved in pain perception and inflammatory processes. The TRPA1 gene was cloned from lung fibroblasts in 1999. Human TRPA1 is composed of 1119 amino acids, located on human chromosome 8q13, with a relative molecular mass of approximately 127kDa, and is a hexatransmembrane protein. The TRPA1 channel was discovered by Professor Ardem Patapoutian, winner of the 2021 Nobel Prize in Physiology or Medicine, and is a class of non-selective ligand-gated cation channels that are involved in sensing noxious stimuli and transmitting noxious signals. More about TRPA1 signaling pathway >>

Ruthenium red, gentamicin, amiloride and gadolinium are the earliest TRPA1 channel antagonists reported in the literature. These non-specific channel blockers have been replaced by more selective TRPA1 antagonists. TRPA1, as an ion channel analgesic target, does not have the addiction and abuse risks of opioids. Because it is upstream of the pain signaling pathway, its targeted drugs will not affect the body’s sensory pattern while blocking pain signals. Combined with its low expression abundance in the central nervous system and heart, this further reduces the risk of central nervous system and cardiac side effects, which is superior to other analgesic targets. As mentioned above, there are currently 6 TRPA1-targeted drugs in the clinical stage, 1 is in the clinical application stage, and 1 has been approved for clinical use.

To assist in the development of TRPA1 drugs, DIMA BIOTECH has developed a full-length human TRPA1 membrane protein using its self-developed Synthetic Nanodisc membrane protein expression technology platform. The protein has a natural conformation and can be used for the screening of small molecule drugs and antibody drugs. In addition, DIMA BIOTECH also has a functional membrane protein development platform, a monoclonal antibody single B cell lead antibody molecule discovery platform, an antibody engineering transformation platform, and an antibody function verification platform, which can provide a variety of protein antibody customization services, antibody humanization, and affinity maturation services for TRPA1 targets.